Which GLP-1 Has the Least Side Effects in the UK? (Wegovy, Mounjaro & the New Pill, 2026)

Updated 22/06/26

‍

Based on the available clinical evidence, Mounjaro (tirzepatide) and Wegovy (semaglutide) are both well tolerated, but most people find Mounjaro causes fewer gastrointestinal side effects at comparable doses, with lower rates of nausea and a higher likelihood of completing treatment. Saxenda (liraglutide) tends to cause more nausea than either, and Byetta (exenatide) has the weakest overall tolerability profile of the group. The right choice still depends on your individual health history, which is why speaking with a clinician before starting any GLP-1 is important.

GLP-1 medications have transformed the treatment of obesity and type 2 diabetes, but choosing between them isn't straightforward. Wegovy, Mounjaro, Saxenda and others all work through similar mechanisms but differ meaningfully in how well most people tolerate them. Nausea, vomiting and other gastrointestinal effects are the most commonly reported concerns, and for many people the side effect profile matters as much as the weight loss results when deciding which medication to try. This guide compares the clinical evidence on side effects across the main GLP-1 options available in the UK.

‍

Comparing Side Effects of Different GLP-1s

Semaglutide (Ozempic, Wegovy)

What it is: Semaglutide, marketed as Ozempic for diabetes management and Wegovy for weight loss, has gained prominence due to its efficacy and positive impact on weight management.

Side Effects:

Common Side Effects

1. Gastrointestinal (GI)

• Nausea (most common, especially during the first few weeks).
• Vomiting, diarrhea, constipation, abdominal bloating, and gas.
• Loss of appetite, making it easier for patients to stick to calorie-restricted diets.

2. Fatigue and headache in the early phase of treatment.

Serious but Less Common Side Effects:

• Pancreatitis: Rare, but a known risk. Pancreatitis (inflammation of the pancreas) can occur in some users.
• Gallbladder Disease: Increased risk of gallstones, especially in individuals with existing gallbladder problems.
• Kidney Issues: There have been reports of acute kidney injury (AKI), particularly in patients who are dehydrated.
• Thyroid Tumors: Animal studies have shown a potential risk of thyroid cancer, although there is no definitive evidence in humans. However, semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).

Scientific Data:

• GI Side Effects: A large phase 3 study found that semaglutide had a lower incidence of severe gastrointestinal side effects compared to liraglutide. However, nausea remains the most commonly reported side effect, especially in the initial stages.
• Tolerability: According to a study, semaglutide was associated with a lower rate of discontinuation due to side effects compared to other GLP-1 medications like liraglutide, making it better tolerated over the long term.

‍

Liraglutide (Victoza, Saxenda)

What it is: Liraglutide, sold under the brand names Victoza for diabetes and Saxenda for weight loss, has been on the market longer than semaglutide.

Side effects:

Common Side Effects:

1. Gastrointestinal (GI):

• Nausea is the most common side effect and tends to be dose-dependent.
• Vomiting, diarrhea, and constipation may also occur.
• Abdominal pain and bloating.

2. Headache and fatigue are common, particularly during the first few weeks.

Serious but Less Common Side Effects:

• Pancreatitis: Rare but noted in some studies. Symptoms include persistent stomach pain, nausea, and vomiting.
• Thyroid Cancer: Studies in rodents have shown a potential link to thyroid tumors (particularly medullary thyroid cancer), but no direct correlation has been established in humans.
• Kidney Issues: Kidney problems, including acute kidney injury, have been reported in a small number of patients, particularly those with pre-existing kidney conditions.

Scientific Data:

• Nausea and GI Side Effects: A study reported that 40% of people on liraglutide experienced nausea during the first few weeks. However, this side effect typically improves after several weeks of use.
• Weight Loss vs. Semaglutide: A study compared liraglutide and semaglutide in terms of efficacy and side effects. The results showed that while both medications led to weight loss, semaglutide was more effective and had a lower frequency of side effects compared to liraglutide, particularly nausea and vomiting.
• ‍

Exenatide (Byetta, Bydureon)

What It Is: Exenatide is a GLP-1 receptor agonist with both short-acting (Byetta) and long-acting (Bydureon) formulations available.

Side Effects:

Common Side Effects

• Nausea, vomiting, diarrhea, abdominal discomfort, and constipation.
• Injection site reactions are more common with Bydureon due to the long-acting formulation.
• Headache and fatigue are common, particularly with the short-acting (Byetta) version.

Serious but Less Common Side Effects:

• Pancreatitis: There is a risk of pancreatitis (inflammation of the pancreas), which is typically associated with a history of pancreatic disorders.
• Kidney Issues: Kidney damage or acute kidney injury has been reported in rare cases.
• Thyroid Cancer: Similar to other GLP-1 drugs, exenatide may have a potential risk for thyroid cancer (particularly medullary thyroid carcinoma), though this has not been definitively proven in humans.

Scientific Data:

A study found that Byetta was associated with more frequent nausea compared to other GLP-1 medications. The long-acting Bydureon was linked to fewer gastrointestinal issues but had an increased incidence of injection site reactions.

‍

Tirzepatide (Mounjaro)

What It Is: Tirzepatide is a GLP-1/GIP receptor agonist that combines the effects of GLP-1 (glucagon-like peptide) and GIP (gastric inhibitory peptide). It is a newer medication available in the UK for managing type 2 diabetes and weight loss.

Side Effects:

Common Side Effects:

• Nausea, vomiting, diarrhea, abdominal pain, and bloating are common, especially at higher doses.
• Some patients report loss of appetite.
• Fatigue and headache.

2. Serious but Less Common Side Effects:

• Pancreatitis: Although rare, there is a risk of acute pancreatitis in some individuals.
• Kidney Issues: There have been reports of kidney-related problems, including acute kidney injury (especially in patients who are dehydrated).
• Thyroid Cancer: Tirzepatide may carry a theoretical risk for thyroid tumors, though this is based on animal studies and has not been confirmed in humans.

Scientific Data:

In the SURPASS trials, tirzepatide showed higher rates of gastrointestinal side effects compared to semaglutide, but these were generally temporary and resolved as treatment continued. Despite this, tirzepatide's weight loss results were remarkable, making it a promising treatment for those focused on both weight loss and glucose control.

‍

Oral Semaglutide (Wegovy Pill)

What It Is: Oral semaglutide, approved by the MHRA in June 2026, is the tablet form of semaglutide, the same active ingredient found in the Wegovy injection. It is the first oral GLP-1 receptor agonist licensed specifically for weight management in the UK, taken once daily on an empty stomach rather than as a weekly injection.

Side Effects:

Common Side Effects:

• Nausea, vomiting, diarrhoea, constipation and abdominal discomfort are common, particularly in the early weeks and after each dose increase.
• Some patients report loss of appetite.
• Fatigue and headache, especially during the adjustment phase.

Serious but Less Common Side Effects:

• Pancreatitis: Although rare, there is a risk of acute pancreatitis. Persistent or severe abdominal pain should be assessed promptly.
• Kidney Issues: Acute kidney injury has been reported, particularly in patients who become dehydrated through vomiting or diarrhoea.
• Thyroid Cancer: As with other GLP-1 medications, animal studies have shown a theoretical risk of thyroid tumours. This has not been confirmed in humans, but the pill is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma.

Scientific Data:

In the OASIS 4 trial, 74% of participants experienced at least one gastrointestinal side effect. Nausea was the most common at 46.6%, and vomiting was reported in 30.9% of pill users, which is higher than rates seen with the Wegovy injection. This is largely attributed to the fasting requirement and the absorption mechanism of the tablet. Despite this, only 6.9% of participants stopped treatment due to side effects, and the majority reported significant improvement by week four of each dose level. Average weight loss was 13.6% over 64 weeks.

‍

Factors Affecting Side Effect Profile

The side effect profile of GLP-1 agonists can vary significantly among individuals due to several factors:

• Individual Variations: Sensitivity to medications can differ widely among patients due to genetic, metabolic, or health factors. For example, individuals with pre-existing gastrointestinal issues may experience heightened nausea.
• Underlying Health Conditions: Pre-existing conditions, such as a history of pancreatitis or thyroid disorders, may increase the risk of serious side effects. Patients with these conditions should discuss their medical history with their healthcare providers before starting GLP-1 therapy.
• Dosage and Administration: The starting dose and titration schedule can significantly impact side effects. For example, initiating treatment at a lower dose and gradually increasing it can help reduce gastrointestinal symptoms. Many providers recommend a titration schedule that allows the body to adjust to the medication, potentially improving tolerance.

‍

Minimising Side Effects

Implementing strategies to manage side effects effectively can enhance the treatment experience for patients using GLP-1 agonists. Here are some practical approaches:

• Gradual Dose Escalation: Starting with a lower dose and gradually increasing can help mitigate side effects. For instance, beginning semaglutide at a low dose (0.25 mg) and gradually adjusting to a higher therapeutic dose can significantly minimise nausea.
• Dietary Adjustments: Patients may benefit from dietary modifications, such as eating smaller, more frequent meals to avoid overwhelming the digestive system. Avoiding high-fat, spicy, or heavy meals can also help prevent gastrointestinal discomfort.
• Hydration: Maintaining proper hydration is crucial, especially for patients experiencing nausea or constipation. Drinking adequate amounts of water can help alleviate symptoms and support overall digestive health.
• Lifestyle Modifications: Incorporating lifestyle changes, such as managing stress through mindfulness practices and ensuring adequate sleep, can improve well-being and potentially reduce side effects. Regular physical activity can also contribute to digestive health and overall wellness.

‍

Consulting with a Healthcare Professional

Patients considering or currently using GLP-1 agonists should seek personalised guidance from healthcare professionals. A thorough discussion about potential side effects and management strategies can significantly impact treatment experiences.

Healthcare providers can tailor a treatment plan that considers individual factors, including medical history, concurrent medications, and lifestyle. This personalised approach ensures that patients maximise the benefits of GLP-1 therapy while minimising adverse effects.

‍

Frequently Asked Questions

Which GLP-1 has the least side effects?

Based on current clinical evidence, Mounjaro (tirzepatide) is generally the best tolerated of the available options, with lower rates of nausea compared to semaglutide at equivalent weight loss doses. That said, individual response varies and the medication that suits you best depends on your health history and how you titrate your dose.

‍
Does the Wegovy pill have fewer side effects than the injection?

Not meaningfully. The pill contains the same active ingredient as the Wegovy injection and produces a broadly similar side effect profile. Nausea and vomiting rates are actually slightly higher with the pill, largely due to the fasting requirement. For a full breakdown, see our guide to Wegovy pill side effects.

‍
Which weight loss injection has the least side effects?

Between Wegovy and Mounjaro, both are well tolerated, but Mounjaro tends to show lower nausea rates in head-to-head data. Saxenda has higher rates of gastrointestinal side effects than either and requires daily rather than weekly injections.

‍
Which GLP-1 is safest?

All GLP-1 medications licensed in the UK have been through rigorous regulatory review and are considered safe for eligible patients under clinical supervision. The serious side effects such as pancreatitis and kidney issues are rare across all options. Your prescriber will assess your individual risk factors before recommending a treatment.

‍
How long do GLP-1 side effects last?

For most people, gastrointestinal side effects are at their worst in the first two to four weeks of each new dose level and improve significantly as the body adjusts. Starting on the lowest dose and titrating slowly is the most reliable way to reduce their severity.

‍
Can I switch GLP-1 medication if I'm struggling with side effects?

Yes. If you are finding one medication difficult to tolerate, switching is a clinical option worth discussing with your prescriber. SheMed's clinical team can help you review your options.

References

1. DeFronzo, R. A., & Triplitt, C. L. (2020). GLP-1 receptor agonists: A clinical perspective on glycemic control, cardiovascular benefits, and weight loss. American Journal of Medicine, 133(11S), S12-S22.
2. Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., & DeFronzo, R. A. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes:
3. National Center for Biotechnology Information. (2022). GLP-1 receptor agonists in diabetes management. In StatPearls [Internet]. StatPearls Publishing.
4. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & Cox, D. A. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.‍
5. Pratley, R. E., Aroda, V. R., Lingvay, I., Ludemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2017). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7):
6. Steinberg, W. M., Nauck, M. A., Zinman, B., Kwan, A. Y. M., Li, Y., & Schmitt, C. (2021). LEADER Trial Investigators. Liraglutide and the Risk of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes:  
7. Nissen, S. E., Wolski, K., Feng, Q., Gyongyosi, M., Lüscher, T. F., Ruschitzka, F., & Muller-Wieland, D. (2016). 
8. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & le Roux, C. W. (2021). 
9. Kumar, S., & Tiwari, S. (2023). The safety and efficacy of GLP-1 receptor agonists for the treatment of obesity: a systematic review and meta-analysis.
10. Reynolds, J. J., Stowasser, M., & Thomas, C. J. (2023). Safety and efficacy of GLP-1 receptor agonists in patients with obesity and diabetes: 

‍